

Long term use, HIV testing and effectiveness in individuals on CAB LA PrEP in the Trio Health Cohort

Richard Elion¹, Gayathri Sridhar², Isobel McEwen¹, Leigh Ragone², Annemiek de Ruiter³, Michael Aboud³, Jean van Wyk³, Kenneth Mayer⁴, Karam Mounzer⁵, Moti Ramgopal⁶, Vani Vannappagari²
¹Trio Health, Louisville CO; ²ViiV Healthcare, Durham, NC; ³ViiV Healthcare, London, England, UK; ⁴Fenway Health, Boston, MA; ⁵PhilaFight, Philadelphia PA; ⁶Midway Specialty Care, Fort Pierce FL

BACKGROUND

- Apretude, or long-acting cabotegravir for pre-exposure prophylaxis (CAB LA PrEP; the first injectable for HIV PrEP FDA approved in December 2021) is indicated in at-risk adults and adolescents to reduce the risk of sexually-acquired HIV-1 infection and injected every 2 months after two initiation injections given 1-month apart.
- CDC guidelines require a negative antigen/antibody (AgAb) test and an undetectable HIV-RNA test prior to initiating CAB LA PrEP (with or without an oral cabotegravir lead-in), plus subsequent HIV status confirmations prior to subsequent injections (negative results with an antigen/antibody-specific test should be confirmed with an RNA test as per label) ¹. With drug resistance as a concern, confirmation of HIV status and good adherence are crucial.
- In this study, we assessed CAB LA PrEP use, HIV testing patterns, persistence, adherence, and HIV acquisition, using electronic medical record (EMR) data from the Trio Health database

METHODS

Study Population:

Adults without HIV who initiated CAB LA for PrEP between December 2021-February 2025 (retrospective EMR data from the Trio Health HIV Network in the U.S. population).

Definitions and Outcomes:

HIV Testing: Either HIV Ag/Ab or RNA assessed for both initial injection (-30 days) and follow-up injections (±7 days).

Adherence:

Continuation injections are based on timing after the prior injection: on-time (53–67 days), delayed (68–112 days), missed (113–127 days), and discontinuation (no injection after >127 days).

Effectiveness:

Incident HIV: detectable HIV RNA and/or positive Ag/Ab test while on CAB LA PrEP.

References: ¹Centers for Disease Control and Prevention. (2025, Feb 10). *Clinical Guidance for PrEP*

Real-world evidence demonstrates the high effectiveness of CAB LA PrEP's in preventing HIV acquisition with high adherence (83% on-time initiation, 62% on-time continuation), though opportunities exist to improve HIV testing practices around subsequent injections.


RESULTS

Population

- 1,696 individuals received at least one injection of CAB LA for PrEP between December 2021 and February 2025. These individuals were followed for a median of 12.1 months (IQR: 5.9-19.8).
- The population had a median age of 34 years (IQR: 28-43), 83% male gender, 14% female, 3% transgender; 52% White, 28% Black or African American, 23% Hispanic or Latino; 70% had prior oral PrEP history.

Persistence


Figure 1: Persistence on CAB LA PrEP Over Time



- 89% completed initiation; 64% of completed initiators were ongoing at end of follow-up
- Median 6 injections (IQR: 4-10) over 13 months
- 36% discontinued; 14% re-initiated within 6 months

Adherence


Figure 2: Adherence to CAB LA PrEP by Injection Phase



- Initiation: 83% had an on time second injection, and 12% delayed
- Continuation: 61% had all continuation injections on-time, 32% with at least one delayed, and 7% with at least one missed
- Median delay of 7 days in the continuation phase


Testing

Figure 3: HIV Testing while on CAB LA PrEP



- Testing compliance decreased from initiation to follow-up
- 65% had both tests at initiation, but only 21% had both tests at all injections
- 45% had at least one test at all follow-up injections

Effectiveness



- 3 HIV diagnosis among 1,696 individuals (0.2%)
- 2 incident cases, 1 potential prevalent case
- All treated with DRV/c/FTC/TAF; two achieved viral suppression, one not yet in 2 months of follow-up
- No resistance mutations detected in individuals one and two, individual 3 was not tested

CONCLUSIONS

- Real-world data on CAB LA PrEP use in the U.S. showed that while a high proportion of individuals had HIV testing prior to initiating CAB LA for PrEP, many had at least one test at subsequent injections.
- Adherence to the dosing schedule was good, with brief delays; however, variations in perceived HIV acquisition risk likely contributed to patterns of discontinuation and reinitiation, while gaps in oral bridging documentation may have inflated delays and discontinuation rates.

Disclaimer

This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.